日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer.

M4205 (IDRX-42) 是一种对癌症中 KIT 相关致癌驱动因子和耐药变体具有高度选择性和强效抑制作用的抑制剂

Esdar Christina, Linde Nina, Blum Andreas, Schieferstein Hanno, Drechsler Christine, Sherbetjian Eva, Petersson Carl, Ross Edith, Leuthner Birgitta, Grädler Ulrich, Dorsch Dieter, Blaukat Andree

Mediator Kinase Inhibitor Selectivity and Activity in Colorectal Cancer

介导激酶抑制剂在结直肠癌中的选择性和活性

Ortiz-Ruiz, Maria J; Popoola, Olajumoke; Mitsopoulos, Konstantinos; Te-Poele, Robert; Samant, Rahul S; Box, Gary; Court, Will; Brandon, Alexis De Haven; Gowan, Sharon; Mallinger, Aurelie; Roe, Toby; Swabey, Kate; Valenti, Melanie; Al-Lazikani, Bissan; Blagg, Julian; Esdar, Christina; Schiemann, Kai; Wienke, Dirk; Eccles, Suzanne A; Workman, Paul; Clarke, Paul A

Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck

抑制抑制剂:IAP抑制剂xevinapant的研发及其在治疗局部晚期头颈部鳞状细胞癌中的应用

Ferris, Robert L; Harrington, Kevin; Schoenfeld, Jonathan D; Tahara, Makoto; Esdar, Christina; Salmio, Satu; Schroeder, Andreas; Bourhis, Jean

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

SHP2抑制影响MET改变肿瘤对替泊替尼的治疗反应

Pudelko, Linda; Jaehrling, Frank; Reusch, Christof; Vitri, Sanziago; Stroh, Christopher; Linde, Nina; Sanderson, Michael P; Musch, Doreen; Lebrun, Catherine Jorand; Keil, Marina; Esdar, Christina; Blaukat, Andree; Rosell, Rafael; Schumacher, Karl Maria; Karachaliou, Niki